Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Glioblastoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Glioma (540
)
Astrocytoma (74
)
Oligodendroglioma (34
)
Ependymoma (8
)
Glioma (540
)
Astrocytoma (74
)
Oligodendroglioma (34
)
Ependymoma (8
)
›
Associations
(234)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-nwgd
Sensitive: A1 - Approval
bevacizumab-nwgd
Sensitive
:
A1
bevacizumab-nwgd
Sensitive: A1 - Approval
bevacizumab-nwgd
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
BRAF V600E
Glioblastoma
BRAF V600E
Glioblastoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.